当前位置: X-MOL首页全球导师 海外导师 › Lalama, Jeffrey

个人简介

Pharmacy Practice Residency, Valley Health Systems – Wincester, VA 2009-2010 Cardiology Specialty Residency, UMass Memorial Medical Center – Worcester, MA 2010-2011 Pharm.D., University of Connecticut, 2009 B.S., Pharmaceutical Studies, University of Connecticut, 2007

研究领域

Anticoagulation Antiplatelet Therapy Cardiology

近期论文

查看导师新发文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

Vandiver, JW, Ritz, LI, Lalama, JT (2016). Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations. Journal Thrombolysis. 41(3):475-481. Lalama JT, Feeney ME, Vandiver JW, Beavers KD, Walter LN, McClintic JR. Assessing an enoxaparin dosing protocol in morbidly obese patients. J Thromb Thrombolysis. 2014 [DOI# 10.1007/s11239-014-1117-y]. Lalama J. Arrhythmias. In: Attridge RL, Miller ML, Moote R, Ryan L, eds. Internal Medicine: A Guide to Clinical Therapeutics. 1st ed. New York, NY: McGraw-Hill; 2013:25. Nelson, A., Lalama, J. Intermediate-Risk Pulmonary Embolism and Fibrinolysis: For Better or For Worse?. In: Linn WD. eds. Topics in Evidence-Based Pharmacy Practice. New York, NY: McGraw-Hill; 2013. http://accesspharmacy.mhmedical.com.dml.regis.edu/updatesContent.aspx?bookid=533&Sectionid=56747651. Accessed October 06, 2014. Lalama, J.T., Feeney, M.E., Vandiver JW, Beavers KD, Walter LN, McClintic JR. Assessing an enoxaparin dosing protocol in morbidly obese patients. J Thromb Thrombolysis. 2014 [DOI# 10.1007/s11239-014-1117-y]. Khan, S., Lalama, J. "What Is The CHANCE That Dual Antiplatelet Therapy Is Effective for Secondary Stroke Prevention?" (update). In: Linn WD, Al-Qadheeb N, Al-Qadheeb N, Havrda D, eds. Topics in Evidence-Based Pharmacy Practice. New York: McGraw-Hill; 2013. http://www.accesspharmacy.com/content.aspx?aID=4000318. Accessed December 2, 2013. Feeney, M., Lalama, J. "Can Newer Anticoagulants AMPLIFY the Initial Treatment of VTE?" (update). In: Linn WD, Al-Qadheeb N, Havrda D, Al-Qadheeb N, Havrda D, eds. Topics in Evidence-Based Pharmacy Practice. New York: McGraw-Hill; 2013. http://www.accesspharmacy.com/content.aspx?aID=4000312. Accessed October 27, 2013 Lalama, J. (2013). Can Newer Anticoagulants AMPLIFY the Initial Treatment of VTE? Topics in Evidence-Based Pharmacy PracticeRetrieved from http://accesspharmacy.mhmedical.com/updatesContent.aspx?bookid=533&Sectionid=45242482 Lalama, J. (2012a). Using Aspirin for Primary Prevention of Vascular and Non-Vascular Outcomes: What Are the Data? Topics in Evidence-Based Pharmacy Practice. Lalama, J. (2012b). Risk of Acute Coronary Events and Dabigatran. Topics in Evidence-Based Pharmacy Practice. Lalama, J., Lewis, P. M., Gore, J., Tran, M.T. & Donovan, J. (2012). How one academic medical center has managed potency changes with unfractionated heparin. Journal of thrombosis and thrombolysis, 1–5. Khan, S., Lalama, J. Can A Fish A Day Keep the ED Away?. In: Linn WD. eds.Topics in Evidence-Based Pharmacy Practice. New York, NY: McGraw-Hill; 2013. http://accesspharmacy.mhmedical.com/updatesContent.aspx?bookid=533&Sectionid=41703424. Accessed April 28, 2014. Lalama, J. (2012). "Dronedarone: Where To Go from Here?" In W.D. Linn, N. Al-Qadheeb, D. Havrda, N. Al-Qadheeb, D. Havrda (Eds), Topics in Evidence-Based Pharmacy Practice. http://www.accesspharmacy.com/content.aspx?aID=4000121. AccessPharmacy. Lalama, J. (2012). "Rivaroxaban: Warfarin's Newest Competitor for Non-Valvular Atrial Fibrillation" (update). In W.D. Linn, N. Al-Qadheeb, D. Havrda, N. Al-Qadheeb, D. Havrda (Eds), Topics in Evidence-Based Pharmacy Practice. http://www.accesspharmacy.com/content.aspx?aID=4000122. AccessPharmacy. Lalama, J., Brackbill, M. (2011) Characterization and Evaluation of Clopidogrel Response Testing in a Community Hospital Setting. J Clinic Experiment Cardiol 2:155. doi:10.4172/2155-9880.1000155.

推荐链接
down
wechat
bug